N1-(8-chloroquinolin-2-yl)-4-(trifluoromethoxy)benzene-1,2-diamine | 1258454-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N1-(8-chloroquinolin-2-yl)-4-(trifluoromethoxy)benzene-1,2-diamine
• 英文别名: 1-N-(8-chloroquinolin-2-yl)-4-(trifluoromethoxy)benzene-1,2-diamine
• CAS: 1258454-36-2
• 化学式: C₁₆H₁₁ClF₃N₃O
• 分子量: 353.731
• InChiKey: KROFVRIRTYNLBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  60.2
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES<br/>[FR] COMPOSÉS BICYCLIQUES UTILES POUR LE TRAITEMENT DE MALADIES CAUSÉES PAR DES RÉTROVIRUS
  申请人：SPLICOS

  公开号：WO2015001518A1

  公开（公告）日：2015-01-08

  Described herein are methods for preventing or treating a retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection. In certain aspects, the methods described herein include contacting a cell in need thereof with compound (I), wherein (II) means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a –CN group, a hydroxyl group, a –COOR1 group, a (C1 -C3)fluoroalkyl group, a (C1 -C3)fluoroalkoxy group, a –NO2 group, a –NR1R2 group, a (C1-C4)alkoxy group, a phenoxy group and a (C1-C3)alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n' is 1 or 2, R' is a hydrogen atom, a halogen atom or a group chosen among a (C1-C3)alkyl group,, a hydroxyl group, a –COOR1 group, a –NO2 group, a –NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a (C1-C4)alkoxy group and a –CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, to prevent or treat the retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection, wherein the retroviral infection is not HIV and the disease caused by the retroviral infection is not AIDS.

  本文描述了一种预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病的方法。在某些方面，所述方法包括将化合物(I)与需要其治疗的细胞接触，其中(II)表示吡啶嗪、嘧啶或吡嗪基团，R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)氟代烷基团、(C1-C3)氟代烷氧基团、-NO2基团、-NR1R2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团，所述烷基可以选择性地被羟基基团单取代，n为1、2或3，n'为1或2，R'为氢原子、卤素原子或在(C1-C3)烷基团、羟基基团、-COOR1基团、- 基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(C1-C3)氟代烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团，Z为N或C，Y为N或C，X为N或C，W为N或C，T为N或C，U为N或C，以预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病，其中逆转录病毒感染不是HIV，由逆转录病毒感染引起的疾病不是艾滋病。
• QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：ABIVAX

  公开号：US20170204063A1

  公开（公告）日：2017-07-20

  The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R″ does not exist when Q is O; R′ independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxy! group, a —COOR 1 group, a —NO2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C 1 -C3)fluoroalkyl group, a —O—P(=O)—(OR 3 XOR 4 ) group, a (C 1 -C 4 )alkoxy group and a —CN group, and can further be a group chosen among: (IIa), (IIIa) or anyone of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of an inflammatory disease.

  本发明涉及一种化合物，其化学式为（I），其中：化学式（II）表示芳香环，其中V为C或N，当V为N时，Q为N或O，但当Q为O时，R″不存在；R′独立表示氢原子或从（C1-C3）烷基，卤素原子，羟基，—COOR1基团，—NO2基团，—NR1R2基团，吗啉基或吗啉基团，N-甲基哌嗪基团，（C1-C3）氟代烷基，—O—P（=O）—（OR3XOR4）基团，（C1-C4）烷氧基和—CN基团中选择的一种基团，并且还可以是选择于（IIa），（IIIa）或其任何药学上可接受的盐，用于治疗和/或预防炎症性疾病。
• COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA
  申请人：Tazi Jamal

  公开号：US20120329796A1

  公开（公告）日：2012-12-27

  The present invention relates to compound (I) wherein: means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO2 group, a —NRiR2 group, a (C 1 -C 4 )alkoxy group, a phenoxy group and a (C 1 -C 3 )alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n′ is 1 or 2, R′ is a hydrogen atom, a halogen atom or a group chosen among a (Ci-C3)alkyl group, a hydroxyl group, a —COOR 1 group, a —NO2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (Ci-C3)fluoroalkyl group, a (C 1 -C 4 )alkoxy group and a —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging. Some of said compounds are new and also form part of the invention.

  本发明涉及化合物(I)，其中：表示吡啶嗪、嘧啶或吡嗪基团，R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)氟烷基团、(C1-C3)氟烷氧基团、-NO2基团、-NRiR2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团，所述烷基可以选择性地被一个羟基基团单取代，n为1、2或3，n'为1或2，R'为氢原子、卤素原子或在(Ci-C3)烷基团、羟基基团、-COOR1基团、- 基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(Ci-C3)氟烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团，Z为N或C，Y为N或C，X为N或C，W为N或C，T为N或C，U为N或C，用作预防、抑制或治疗与早衰有关的病理或非病理状态的药剂。其中一些化合物是新的，也是本发明的一部分。
• miRNA-124 as a biomarker of viral infection
  申请人：Splicos

  公开号：EP2757161A1

  公开（公告）日：2014-07-23

  A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.

  将至少一种 miRNA（所述至少一种 miRNA 为 miR-124）用作病毒感染或所述病毒感染治疗疗效的生物标志物。
• QUINOLINE DERIVATIVES FOR USE INE THE TRAEATMENT OF INFLAMMATION DISEASES
  申请人：ABIVAX

  公开号：EP3669873A1

  公开（公告）日：2020-06-24

  The present disclosure relates to quinoline derivatives of Formula (I): wherein each R is independently hydrogen, halogen, -CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, -NO2, -NR1R2, (C1-C4)alkoxy, phenoxy, -NR1-SO2-NR1R2, -NR1-SO2-R1, -NR1-C(=O)-R1, -NR1-C(=O)-NR1R2,-SO2-NR1R2, -SO3H, -O-SO2-OR3, -O-P(=O)-(OR3)(OR4), -O-CH2-COOR3, (C1-C3)alkyl, said alkyl being optionally mono- or di-substituted by a hydroxyl group; each R' is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, -NO2, -NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, -O-P(=O)-(OR3)(OR4), -CN, or other groups; for use for preventing and/or treating inflammatory disease, disorder, or conditions.

  本公开涉及式 (I) 的喹啉衍生物： 其中每个 R 独立地为氢、卤素、-CN、羟基、(C1-C3)氟烷基、(C1-C3)氟烷氧基、(C3-C6)环烷基、-NO2、-NR1R2、(C1-C4)烷氧基、苯氧基、-NR1-SO2-NR1R2、-NR1-SO2-R1、-NR1-C(＝O)-R1、-NR1-C(＝O)-NR1R2、-SO2-NR1R2、-SO3H、-O-SO2-OR3、-O-P(＝O)-(OR3)(OR4)、-O-CH2-COOR3、(C1-C3)烷基，所述烷基可任选被羟基单取代或二取代；每个 R'独立地为氢、(C1-C3)烷基、羟基、卤素、- 、-NR1R2、吗啉基、吗啉基、N-甲基哌嗪基、(C1-C3)氟烷基、(C1-C4)烷氧基、-O-P(=O)-(OR3)(OR4)、-CN 或其他基团；用于预防和/或治疗炎症性疾病、紊乱或病症。